Learn more about the role of Tuberculosis in cancer and how a simple vaccine supports the immune system to fight it.

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...

The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study,” published in the ...

Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

CG Oncology (CGON) announced that 83 out of 110 patients achieved a complete response at any time in a Phase 3 study of cretostimogene ...

U.S. Urology Partners is one of the first providers ... receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive ...